CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发急性淋巴细胞白血病年轻患者接受 Tisagenlecleucel 治疗后发生噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征：磷酸依托泊苷输注后显著恢复的病例报告
英文原题：Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.
查看英文原题
Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞输注后继发噬血细胞性淋巴组织细胞增多症/巨噬细胞活化综合征（HLH/MAS）非常罕见，且多数致死。目前尚未制定此类并发症的治疗建议。我们报告一例复发性急性淋巴细胞白血病年轻患者，在接受tisagenlecleucel输注后发生HLH/MAS，采用依托泊苷磷酸盐（EP）治疗后病情显著恢复。我们建议将监测CAR-T 输注后HLH/MAS纳入随访；EP治疗似乎有助于控制这一严重且罕见的并发症。
展开英文摘要原文
The occurrence of a secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) after CAR T-cell infusion is very rare and mostly fatal. Treatment recommendations for such a complication are not yet established.
Here, we report the dramatic recovery of HLH/MAS following tisagenlecleucel infusion in a young patient with relapsed acute lymphoblastic leukemia using etoposide phosphate (EP).
We propose that monitoring for the occurrence of HLH/MAS should be part of surveillance after CAR T-cell infusion and that EP treatment appears to be useful to control this severe and rare complication.
论文信息
- 作者
- Peterlin P、Garnier A、Le Bourgeois A、Jullien M、Seguin A、Eveillard M、Béné MC、Guillaume T
- 单位
- Hematology Department, Nantes University Hospital, Nantes, France.France
- 文献类型
- 病例报告
- 期刊
- Acta haematologica2022
- 原文标识
- PubMed 35724631 · DOI 10.1159/000525576